AIDS activists continue campaign to stop EU-India FTA

3 March 2011

The international medical humanitarian organization Medecins Sans Frontieres (MSF) marched alongside more than two thousand people living with HIV from across Asia and the United Nation’s Special Rapporteur on the Right to Health in New Delhi yesterday, urging the Indian government to stand strong amid pressure from the European Union to accept provisions in a free trade agreement (FTA) that would restrict access to affordable medicines, as sensitive negotiations were taking place in Brussels (The Pharma Letters passim).

“More than 80% of the AIDS drugs our medical practitioners use to treat 175,000 people in developing countries are affordable generics from India,” said Paul Cawthorne, of MSF’s Campaign for Access to Essential Medicines. “Beyond AIDS, we rely on producers in India for drugs to treat other illnesses, such as tuberculosis and malaria. We cannot afford to let our patients’ lifeline be cut,” he added.

EU pushing for IP provisions beyond trade rule requirements

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics